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Long-term, localized delivery of small molecules from a biodegrad-
able thin film is challenging owing to their low molecular weight
and poor charge density. Accomplishing highly extended con-
trolled release can facilitate high therapeutic levels in specific
regions of the body while significantly reducing the toxicity to
vital organs typically caused by systemic administration and de-
creasing the need for medical intervention because of its long-
lasting release. Also important is the ability to achieve high drug
loadings in thin film coatings to allow incorporation of significant
drug amounts on implant surfaces. Here we report a sustained
release formulation for small molecules based on a soluble charged
polymer–drug conjugate that is immobilized into nanoscale, con-
formal, layer-by-layer assembled films applicable to a variety of
substrate surfaces. We measured a highly predictable sustained
drug release from a polymer thin film coating of 0.5–2.7 μm that
continued for more than 14 mo with physiologically relevant drug
concentrations, providing an important drug delivery advance. We
demonstrated this effect with a potent small molecule nonsteroidal
anti-inflammatory drug, diclofenac, because this drug can be used
to address chronic pain, osteoarthritis, and a range of other critical
medical issues.
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There is a compelling need for long-term, controlled drugrelease for sustained treatment of chronic or recalcitrant med-
ical conditions and diseases, especially when using small molecules
with abundant targets throughout the body. For example, antibac-
terial therapy typically requires sustained local concentrations for
periods of days to weeks, whereas some diseases, such as tubercu-
losis, necessitate daily doses of antibiotics for at least 6 mo (1).
Other diseases also have demonstrated benefits from a long-term
multimonth drug regimen, including cystic fibrosis (2), ankylosing
spondylitis (3), and chronic uveitis (4).
Chronic pain may best illustrate the positive multifaceted
impact of long-term drug treatment. Described as pain that extends
beyond the expected period of healing, it is a widespread and de-
bilitating ailment underpinning an unwanted dependency on nar-
cotic medications. Often misdiagnosed and undertreated, chronic
pain affects roughly 20% of US adults, and 25% of those age >45 y
(5). Sometimes considered a silent epidemic, chronic pain calls for
advanced pain treatments (6).
Nonsteroidal anti-inflammatory drugs (NSAIDs), one of
a number of approaches to pain relief, strike a preferable bal-
ance between analgesic effectiveness and adverse reactions (7).
Although the potentially adverse effects of NSAIDs are minimal
compared with alternatives, prolonged and frequent use can lead
to adverse drug reactions, especially in adults aged 65 and older
(8). Given that NSAIDs are the most frequently prescribed med-
ications for osteoarthritis (9), the ability to treat this persistent pain
while avoiding the associated adverse drug reactions could have
tremendously positive effects for millions of people.
Localized drug delivery is an attractive route for substantially
reducing systemic dosages while maintaining localized saturation
(10). Locally delivered diclofenac has shown similar analgesia to
systemically delivered diclofenac but with significantly fewer
adverse reactions (11), which led the way for Food and Drug
Administration approval of topical formulations: Voltaren Gel
(Novartis) and Pennsaid (Mallinckrodt). Although topical diclofe-
nac has demonstrated the promise of localized delivery, it requires
frequent administration (4 times daily), with bioelimination oc-
curring within hours (12). Less frequent dosing has shown a
positive influence on outcome (13), which would tremendously
benefit several other applications including orthopedics and
wound healing.
Long-term small molecule release is typically difficult, and
formulations based on biodegradable materials, such as poly
(lactic-co-glycolic acid) (PLGA), can extend release for days up
to several weeks and, in some notable cases, multiple months
(10). Factors including water permeation, decreased pH owing
to acid buildup in the case of polymers like PLGA, structural
instability (e.g., crack formation), erosion, and drug diffusivity,
among others, form a complex picture with a ceiling on release
duration (14). Their small size and hydrophobicity makes con-
trolling the release of small molecules especially difficult, because
they diffuse rapidly (15). Sustained release also can be achieved
from other polymeric vehicles, ranging from gels to bulk degrad-
able plastics (16, 17); these materials have been able to sustain
drug release for up to a few months at best when mitigating the
aforementioned obstacles. In addition, these inherent limitations
make achieving extensive release periods difficult because of the
need for excessive quantities of material, changes in material
properties with time, and ultimate constraints on drug loading
Significance
Drug release from implants and coatings provides a means for
local administration while minimizing systemic toxicity. Con-
trolled release can provide a slowly eluting drug reservoir to
maintain elevated therapeutic levels. Devices based on degrad-
able polymer matrices can control drug release for multiple
weeks, but longer durations typically require bulky, nondegrad-
able devices. Using a combination of a polymer–drug conjugate
and its electrostatic thin film assembly, we discovered a predict-
able long-term sustained release of more than 14 mo, far ex-
ceeding the duration noted in most previous reports, especially
those from biodegradable matrices. Because of the substantial
drug loading, nanoscale films were able to maintain significant
concentrations that remained highly potent. We report a versa-
tile, long-term drug delivery platform with broad biomedical
implications.
Author contributions: B.B.H. and P.T.H. designed research; B.B.H., M.-H.P., and S.R.H.
performed research; B.B.H., M.-H.P., and P.T.H. analyzed data; and B.B.H. and P.T.H. wrote
the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission. G.D. is a guest editor invited by the Editorial
Board.
1To whom correspondence should be addressed. Email: hammond@mit.edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1323829111/-/DCSupplemental.
www.pnas.org/cgi/doi/10.1073/pnas.1323829111 PNAS Early Edition | 1 of 6
M
ED
IC
A
L
SC
IE
N
CE
S
density owing to the thermodynamic constraints of traditional
polymer molecular blends. Achieving sustained multiple-month
long-term release usually requires a nondegradable physical re-
lease device, such as Illuvien (Alimera Sciences), a cylindrical in-
traocular insert with a semipermeable membrane that can sustain
release for more than 1 y (18). In pain management, some non-
degradable implants capable of sustained release for a few months
have been investigated (19), but a biodegradable, long-term, sus-
tained drug delivery formulation remains highly desired.
The layer-by-layer (LbL) assembly technique has uniquely
demonstrated the construction of thin films under benign aque-
ous conditions for controlled release of numerous therapeutics,
including proteins, growth factors, peptides, and small molecules
(20). This technique relies on numerous intermolecular inter-
actions (e.g., electrostatic) for assembly and stability; thus, the use
of high molecular weight polyelectrolytes can result in films
that are extremely robust and capable of coating a variety of
materials and substrate geometries. A common challenge in any
small molecule drug delivery system is the incorporation and
subsequent controlled release of poorly charged or low molecular
weight species. Our laboratory has investigated a number of LbL-
based biodegradable strategies for controlled small molecule re-
lease, including direct incorporation of drug into the film (21, 22)
and physical entrapment in other charged systems (23, 24), with
a longest sustained release of 3 wk. Changes in the aqueous en-
vironment, such as pH or ionic strength, also can facilitate un-
desirable film deterioration or drug elution that dramatically
affects release kinetics (25).
Here we report the development of a polymer–drug conjugate
and its assembly into an LbL thin film for long-term sustained
drug delivery. We used diclofenac as a model small molecule and
measured its release for longer than 14 mo from biodegradable
conformal coatings. Films as thin as ∼500 nm demonstrate the
capability for substantial diclofenac loading, and once released,
the drug maintains its anti-inflammatory activity and potency
despite prolonged hydration at elevated temperatures. The possi-
bility of such long-term controlled release of active small molecule
drugs from a biodegradable, nanoscale thin film has implications
for drug delivery in a broad spectrum of fields.
Results and Discussion
Polymer–Drug Conjugate. LbL assembly is based on alternating
adsorption of charged (or otherwise complementary) species.
We used the biologically derived polyacid poly(L-glutamatic
acid) (PGA), because it is composed of a natural L-amino acid
and ultimately can be broken down and resorbed by the body. In
addition, the pendant carboxylates allows for a high level
of drug conjugation while maintaining sufficient free acid
groups for electrostatic complexation. Similar PGA-based LbL
approaches have demonstrated in vitro (26) and in vivo (27)
bioactivity from functionalized films, as well as for cellular
delivery of doxorubicin (28).
To generate our polymer–drug conjugate, we relied on a two-
step strategy that first forms a diclofenac prodrug with hydroxyl
functionality and is subsequently conjugated to the polymer
backbone. As shown in Fig. 1, the carboxylic acid of diclofenac 1
was activated with 1,1′-carbonyldiimidazole and then esterified
with excess triethylene glycol (TriEG). The resulting prodrug,
a TriEG-diclofenac conjugate (TriEG-Diclof) 2, was purified and
subsequently coupled to PGA via Steglich esterification using
N,N′-dicyclohexylcarbodiimide and 4-dimethylaminopyridine. This
resultant polymer–drug conjugate, PGA-TriEG-Diclof 3, had
9.8 mol% (19.5 wt%) of the PGA monomer repeat units func-
tionalized with diclofenac. Diclofenac, similar to other small mole-
cules, has a limited aqueous solubility of 2.4 μg/mL (29). Although
2 was found to be water-insoluble (30), 3 was well solubilized at
50 mg/mL, equivalent to 9.8 mg/mL diclofenac. By virtue of at-
tachment to a large polyacid, diclofenac’s solubility in water in-
creased 4,000-fold over its acid form and more than fivefold over
its sodium salt [1.9 mg/mL (29)], indicating that significant sta-
bility is imparted by conjugation to a hydrophilic backbone, anal-
ogous to observations with other PGA–drug conjugates (31).
Furthermore, the high drug density of the polymer conjugate pro-
vides the opportunity to achieve substantial film loading of the drug
in LbL films.
To characterize diclofenac tethering to the PGA backbone, we
analyzed our various diclofenac-based compounds by HPLC. A
typical chromatogram for diclofenac is shown in Fig. 2A with
a small peak at 8 min that appears to be a low-level impurity.
Neither TriEG-Diclof (Fig. 2B) nor PGA-TriEG-Diclof (Fig.
2C) solutions produced a significant HPLC signal, indicating that
chemical modification substantially changes diclofenac’s char-
acteristic affinity for the C18 HPLC column, and that the product
contains no detectable free diclofenac, reaffirming complete co-
valent modification. Quantitative ester hydrolysis of PGA-TriEG-
Diclof with sodium hydroxide (100 mM, pH ∼11) overnight at
37 °C showed that diclofenac is regenerated (Fig. 2D).
Before the incorporation of PGA conjugates into LbL films,
we first investigated the rate of ester hydrolysis of the PGA
conjugates under physiological conditions, which is an important
determinant of whether therapeutically relevant concentrations
of diclofenac can be generated on a biologically important time
scale. Using pseudo first-order reaction kinetics, we calculated
the initial rates of diclofenac release in PBS at pH 7.4 to de-
termine their rate constants (kobs) at 19 °C, 37 °C, and 50 °C
(Table 1). As expected, hydrolysis accelerated with increasing
temperature, as characterized by the positive activation energy
(Ea) of 67 ± 12 kJ/mol. In analogous polymer–drug systems, the
half-life (t1/2) at pH 7.4 and 37 °C of small molecules conjugated
to dextran can vary greatly with the drug type and polymer
backbone. For example, 5-fluorouracil (t1/2 = 0.73 d) (32), ben-
zoate (t1/2 = 7.5 d) (33), naproxen (t1/2 = 7.6 d) (34), and keto-
profen/ibuprofen/naproxen (t1/2 = 7.8 d/5.3 d/4.2 d) (35) have
half-lives of roughly 1 wk or less, whereas other variations, such
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Fig. 1. Synthetic scheme of the polymer–drug conjugate. (A) The carboxylic
acid moiety of diclofenac 1 is activated with 1,1′-carbonyldiimidazole and
subsequently esterified with TriEG to form the TriEG-Diclof prodrug 2. (B) After
purification, 2 is then conjugated to poly(L-glutamic acid) via Steglich esteri-
fication with N,N′-dicyclohexylcarbodiimide and 4-dimethylaminopyridine to
yield the PGA-TriEG-Diclof conjugate 3.
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Fig. 2. Chromatograms for the fluorescent intensity of stock diclofenac 1
(A), the TriEG-Diclof prodrug 2 (B), the polymer–drug conjugate 3 (C), and
hydrolyzed polymer–drug conjugate (D) as analyzed by HPLC.
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as starch-naproxen (t1/2 = 33 d) (34) and hyaluronic acid-corti-
sone (t1/2 = 3.6 d) (36), demonstrate a potentially broad range.
We found that our polymer–drug compound has a substantially
longer half-life compared with most reported conjugates (Table
1), making it an ideal candidate for long-term sustained release
formulations.
Numerous factors can affect the rate of ester hydrolysis. For
example, nearest- neighbor groups are influential (37), with
negative charges along the polymer backbone slowing (38) and
positive charges accelerating bond cleavage (39). In addition,
electron- donating or -withdrawing groups near the ester can
modulate hydrolysis (40), as can steric bulk that limits accessi-
bility (34). If a linker is present, as in our case, its hydrophobicity
can slow ester cleavage (41). The combination of a high negative
charge along the PGA backbone, which is increased as the ester
hydrolyzes, and hydrophobicity of the pendant TriEG-Diclof is
likely a significant factor contributing to the slow release kinetics
that we observed.
In addition to the linker’s hydrolytic susceptibility, the hy-
drophobicity of the pendant side-chains along a charged, hy-
drophilic backbone has also shown the propensity to form
colloidal aggregates that exhibit a hydrophilic outer shell and
hydrophobic core (42). Some amphiphilic polymers, such as
those with randomly functionalized pendant hydrophobic moie-
ties, also can generate hydrophobic intramolecular nanodomains
within a single molecule (43). Our studies of PGA-TriEG-Diclof
in aqueous solution at 1 mg/mL by dynamic light scattering
showed hydrodynamic diameters of 124.9 ± 1.6 nm in 100 mM
sodium acetate, pH 6.3 (conditions used for assembly with chi-
tosan), and 28.8 ± 4.7 nm in 10 mM sodium phosphate, pH 7.4
(conditions used for assembly with PLL). In addition, their
critical micelle concentrations were 4.2 μg/mL and 9.9 μg/mL,
respectively. These measurements reveal the presence of micel-
lar aggregates due to the hydrophobicity of the pendant diclo-
fenac and hydrophilicity of the PGA backbone. The difference in
size depending on solution conditions is likely a consequence of
the lower ionization and increased charge shielding occurring in
100 mM sodium acetate, pH 6.3 compared with 10 mM sodium
phosphate, pH 7.4; the reduced electrostatic repulsion in the
former allows for higher aggregation numbers and thus larger
particle sizes (44). Because of the self-assembly into micellar
aggregates, pendant ester linkages are sequestered into the hy-
drophobic core, which is likely a major factor in the slow diclo-
fenac release kinetics that we observed.
Multilayer Films. Solution-phase kinetics indicate that controlled
diclofenac release can be facilitated by ester hydrolysis from
a polymer backbone; however, the polymer–drug conjugate itself
is soluble in water and cannot be used to create a stable thin film
coating or similar construct for controlled localized release.
Using an LbL assembly technique, we were able to immobilize
nanoscale layers of PGA-TriEG-Diclof from aqueous solutions
via polyelectrolyte complexation with a cationic polymer atop
a substrate surface. Repeated deposition of (Polycation/PGA-
TriEG-Diclof) layers allows for control over film thickness and
drug payload. These bilayers were constructed with polycations
of poly(L-lysine) (PLL) at pH 7.4 and chitosan at pH 5.0, with
PGA-TriEG-Diclof at pH 7.4 and 6.3, respectively. Their film
growth revealed a concomitant increase in thickness with the
number of bilayers, a characteristic feature of LbL-based films
(45) (Fig. 3 A and B).
The bilayer thickness of an LbL film can vary from sub-
nanometer to tens of nanometers depending on various factors,
including pH, ionic strength, and degree of ionization of the
adsorbing polymer chains. These effects, among others, can
mechanistically influence the polyelectrolyte’s ability to diffuse
into, out of, and within hydrated multilayer films during film
assembly (46). In addition, the size of the PGA-TriEG-Diclof
micellar aggregate may restrict its diffusivity within the film. Other
electrostatic-based LbL films with block copolymer micelles have
shown linear growth behavior after the initial few layers, with bi-
layer thicknesses of ∼100 nm, suggesting the deposition of multi-
ple micelle layers, a large fraction of the other film component, or
a combination thereof. We observed a similar growth behavior in
(PLL/PGA-TriEG-Diclof)n films in which relatively little material
is deposited for the first few layers, but the assembly transitions to
considerably thicker deposition beyond five bilayers (Fig. 3A).
PLL (pka∼9.9 (47)) is significantly charged with a random coil
conformation (48) at pH 7.4 during deposition, and its inte-
diffusivity can be a considerable factor, given that films of (PLL/
PGA)n are well known to demonstrate exponential growth owing
to interdiffusion (49), with the diffusivity of PLL independent of
the diffusivity of the polyanion (50). Linear regression of this
latter growth phase (Fig. 3A) revealed a deposit of 75.1 ± 5.1 nm
Table 1. Hydrolysis kinetics of PGA-TriEG-Diclof in PBS, pH 7.4
T, °C kobs, × 10
−8 s−1 t1/2, d
19 0.311 ± 0.005 2,577
37 2.29 ± 0.03 350
50 4.14 ± 0.29 194
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Fig. 3. Growth curves of (PLL/PGA-TriEG-Diclof)n (A) and (chitosan/PGA-
TriEG-Diclof)n (B) films.
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Fig. 4. Diclofenac release profiles from (PLL/PGA-TriEG-Diclof)n films (A and C)
and (chitosan/PGA-TriEG-Diclof)40 films (B and D). Full-scale (A and B) and the
first 60 d (C and D) are shown. The symbols represent measured data, and solid
lines represent first-order fits (A and B) or linear regressions (C and D).
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(R2 = 0.991) per bilayer, suggesting considerable deposition. In
contrast, (chitosan/PGA-TriEG-Diclof)n films were considerably
thinner with no observed induction period, with 11.0 ± 0.3 nm
(R2 = 0.9994) deposited per bilayer. The growth behavior of
a (chitosan/PGA)n film can range from linear to exponential
depending on the polyelectrolyte’s charge density during film
deposition (51), which contributes significantly to the thickness
of film per bilayer (52). When chitosan [pKa∼6.5 (53)] is well
ionized and attains a flat and extended conformation, it dem-
onstrates linear film growth (51), as we observed. The seemingly
small contribution to thickness of the polymer–drug conjugate
despite its micelle size (∼125 nm) is likely related to spreading of
the aggregates and possible rearrangement of the structures
on adsorption.
The elution of diclofenac from these films demonstrates a
long-lasting multimonth release. We measured release for more
than 14 mo in the PLL-based films and for more than 5 mo in the
chitosan-based films (Fig. 4). In the latter case, diclofenac re-
lease from the thinner 10- and 25-bilayer films was too low for
reliable detection by HPLC. Overall, the release kinetics of
diclofenac from these LbL films can be fit to pseudo first-order
kinetics, as shown by the curves in Fig. 4 A and B. This is not
surprising, given that diclofenac release by ester hydrolysis in the
hydrated LbL film occurs through the same mechanism as in
solubilized PGA-TriEG-Diclof. Film assembly through electro-
static complexation of the polyanionic backbone accommodates
its immobilization into the film while maintaining the polymer–
drug conjugate’s aqueous solvation and accessibility, thereby
allowing its use as a localized drug delivery strategy. The kinetic
rate constants, kobs, can be similarly calculated from these re-
lease curves; we found values of 5.6 × 10−8 s−1 for the PLL-based
film and 1.7 × 10−7 s−1 for the chitosan-based film. Both of these
film-based rate constants are greater than that of solubilized PGA-
TriEG-Diclof (Table 1) under identical conditions of PBS, pH 7.4
at 37 °C. This film-based rate acceleration is likely a consequence
of a combination of the aforementioned micellar disruption on
film assembly and the polyion’s electrostatic complexation, which
neutralizes much of the backbone nearest-neighbor negative
charges and thus may reduce the inhibition of ester side-chain
hydrolysis (38).
A highly desirable feature for controlled release systems is
zeroth-order release kinetics, in which the rate of drug release
can balance its bioelimination to sustain a therapeutic concen-
tration (10). Linear regression of the drug released from each of
our films in the first 2 mo demonstrated constant rates of
diclofenac elution from both PLL-based (Fig. 4C) and chitosan-
based (Fig. 4D) systems. An initial burst release of drug is
commonly observed in controlled-release systems for small
molecules owing to their low molecular weights (54); this is
frequently undesirable because it can be uncontrollable, irre-
producible, and toxic resulting from a rapid elevation in local
drug concentration (55). With our strategy of using a polymer–
drug conjugate that is electrostatically immobilized into a film,
the drug release is mediated by ester hydrolysis, eliminating this
potentially deleterious initial burst release.
The differences in diclofenac release rates from PLL-based
and chitosan-based films become more evident when their re-
lease profiles from 40-bilayer films are presented in terms of the
mass of diclofenac released per film volume, as shown in Fig. 5.
Our observation of faster release rates from chitosan-based films
compared with PLL-based films likely reflects the compositional
differences within the films, including less water accessibility for
the latter, given that greater hydrophobicity has been found to
slow hydrolysis, whereas increased hydrophilicity accelerates
hydrolysis (56). We suspect that the polycation charge density
(e.g., PLL and chitosan), ionic strength, and pH of assembly
conditions also contribute to differences in the effective ionic
cross-link density and degree of water swelling within the films,
affecting hydrolysis rates and influencing the presence of hy-
drophobic regions [i.e., self-assembly of pendant diclofenac into
hydrophobic pockets (57)]. We gauged the relative water content
in these films by comparing their swelling on hydration in PBS,
pH 7.4. The PLL-based films showed relatively moderate swell-
ing (38 ± 12%), whereas chitosan-based films revealed signifi-
cantly greater swelling (116 ± 14%), indicating its greater
hydrophilicity. This also corresponds with the more rapid diclo-
fenac elution seen from chitosan-based films. Furthermore, the
change in pH between the assembly conditions and release con-
ditions for chitosan films also may facilitate increased water acces-
sibility of the ester linkages, given that pH-induced morphological
changes in LbL films can cause film swelling and rearrangement
and, consequently, increased water access to moieties previously
hidden in hydrophobic pockets (58).
A myriad of factors can contribute to the characteristics of
controlled-release films, and, interestingly, our system showed
significantly higher loading and extended release compared with
another LbL-film based on a polymer–drug conjugate, (chitosan/
hyaluronic acid-paclitaxel)n films (59). For our PLL-based and
chitosan-based films of 40 bilayers (Fig. 5), diclofenac loading
densities were 295 μg/mm3 (30 wt%) and 259 μg/mm3 (26 wt%),
respectively. These PLL-based and chitosan-based films are also
significantly greater in drug loading and release duration of
diclofenac than in other nonconjugate LbL-based (24, 25),
PLGA-based (60), and lipid nanoparticle-based systems (61).
Although ester hydrolysis facilitates diclofenac liberation and
elution, the polypeptide-based film remains intact. We found
that after 10.6 mo of incubation and drug release, the (PLL/
PGA-TriEG-Diclof)40 dry film thickness was 2.9 ± 0.2 μm,
comparable to its thickness before release (2.7 ± 0.5 μm), in-
dicating that any small changes in charge distribution and net
charge balance within the LbL films during diclofenac release
are insufficient to cause destabilization of the films. We propose
that during hydration, the film effectively swells and the pendant
drug is believed to uniformly undergo hydrolysis-based release
over time. This leaves the poly(L-glutamic acid) backbone intact
in the LbL film, thereby making the film less sensitive to some of
the complexities (e.g., autocatalysis, nonuniformity, pore for-
mation, cracks, structural collapse) that plague certain other
Fig. 5. Mass of diclofenac per film volume released from (PLL/PGA-TriEG-
Diclof)40 and (chitosan/PGA-TriEG-Diclof)40 films. Symbols represent mea-
sured data; solid lines, first-order fits.
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Fig. 6. COX inhibition activity of diclofenac-based compounds. Diclofenac
released from LbL films was examined for COX inhibition activity at the
concentration released into PBS, pH 7.4.
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drug release systems (14). This behavior also differs from the
previously developed erosion-based, hydrolytically degradable
LbL films used for controlled delivery that rely on poly(β-amino
ester)s with cleavable ester linkages along the polymer backbone.
The hydrophobicity of these degradable polycations can be tuned,
as can the release kinetics from the film (62). Differential rates of
water uptake and, consequently, hydrolysis-mediated film erosion
in such systems allow for diverse release kinetics, but are not as
easily adapted to the controlled release of small molecules, which
are bound to undergo some rapid diffusion with swelling, given
that they rely on trapping of molecules within the ionic network
rather than on covalent conjugation.
Whereas film degradation by polypeptide bond hydrolysis is rel-
atively inconsequential comparedwith the rate of diclofenac release,
its proteolysis can accelerate disassembly. This biodegradability is
a coveted feature for implantable materials, and its rate is highly
dependent on the biological fluid’s enzyme composition. Inves-
tigations into tuning of proteolytic susceptibility have shown that
although somehumanproteases have poor activity against LbL films
(63), film characteristics including covalent cross-linking (64), L- or
D-polypeptides (65), and terminal layer charge (66), among others,
can enhance or inhibit degradation. In addition, antifouling mod-
ifications like PEGylation (67) andmixed-charge nanodomains (68)
can introduce a protein resistance that reduces enzyme contact with
the film. This versatility in LbL-assembled films, coupled with the
nonenzymatic hydrolytic release mechanism, can readily accom-
modate a variety of modifications that specifically tune film char-
acteristics to the desired application.
Anti-Inflammatory Activity. We examined the efficacy of diclofe-
nac derived from our various formulations to identify potentially
deleterious effects from the synthesis, film assembly, and release
process. By investigating diclofenac’s inhibition of COX-1 ac-
tivity in vitro, we can gain insight into its ability to reduce the
downstream effects of inflammation and pain. As shown in Fig.
6, stock diclofenac yielded substantial COX inhibition, whereas
polymer conjugation (i.e., PGA-TriEG-Diclof) eliminated it.
This inactivation is likely related to the masking of diclofenac’s
carboxylic acid by esterification and the introduction of steric
bulkiness from the polymer-linker component, both of which can
prevent binding with the COX enzyme (69). To regenerate ac-
tivity, we hydrolyzed the ester linkages and found that diclofenac
recovered from the polymer–drug conjugate also retained its
functionality for COX inhibition (Fig. 6). In our controlled-
release films, we incorporated PGA-TriEG-Diclof into electro-
statically assembled LbL films incubated under physiological
conditions of PBS, pH 7.4 at 37 °C for multiple months, possibly
submitting diclofenac to the degradative effects of prolonged
hydration and elevated temperature. Therefore, we tested the
undiluted release of diclofenac at 0.5, 3.0, and 6.0 mo from (PLL/
PGA-TriEG-Diclof)40 films and found that the drug, as released,
retained substantial COX inhibition at a similar level as stock
diclofenac solutions. We have previously found that therapeutics
released from LbL films remain active, even after weeks of in-
cubation, possibly stemming from the stabilization provided by
the milieu of intermolecular interactions with the surrounding
matrix. In addition, the degradation pathways for diclofenac in-
volve mainly intramolecular cyclization with its carboxylic acid
(70), which may be inhibited by its esterification.
We also examined the intrinsic potency of the LbL-incorporated
diclofenac by measuring the IC50 (concentration required for 50%
inhibition) of COX. As shown in Table 2, the diclofenac IC50 was
comparable in an unfunctionalized diclofenac control, hydrolyzed
drug from PGA-TriEG-Diclof film, and drug released from (PLL/
PGA-TriEG-Diclof)40 film. This finding confirms that none of the
steps—including synthesis of the polymer–drug conjugate, LbL as-
sembly into a film, long-term hydration and incubation at elevated
temperature, and ester hydrolysis to regenerate the drug—has a
deleterious effect; drug efficacy was maintained throughout the
long-term release.
Conclusions
Long-term small molecule treatment from a biodegradable de-
vice can have a highly positive impact on a broad spectrum of
chronic or recalcitrant medical issues. We have generated a
polymer–drug conjugate capable of relatively slow release based
on ester hydrolysis and incorporated it into LbL films, yielding a
robust nanoscale film with substantial payload that elutes active
drug for more than 14 mo. This versatile strategy is applicable to
a broad range of therapeutics and represents a promising approach
to treating a multitude of targets.
Materials and Methods
Multilayer films were assembled by incubation for 10 min in polycation so-
lution; followed by 10-s, 20-s, and 30-s H2O rinses; then 10 min of polyanion
solution; and finally more 10-s, 20-s, and 30-s H2O rinses. For (PLL/PGA-TriEG-
Diclof)n films, both PLL and PGA-TriEG-Diclof were formulated at 1 mg/mL in
10 mM sodium phosphate, pH 7.4. For (chitosan/PGA-TriEG-Diclof)n films,
2 mg/mL chitosan in 100 mM sodium acetate, pH 5.0, and 1 mg/mL PGA-
TriEG-Diclof in 100 mM sodium acetate, pH 6.3, were used. (The latter pH
was chosen because of the limited solubility of PGA-TriEG-Diclof below
pH 6.3.) Film-based diclofenac release was studied by immersion in 1 mL of
PBS, pH 7.4 at 37 °C for predetermined times, after which films were
transferred to fresh PBS solution. Films released into solution were analyzed
by HPLC for COX-1 inhibition. COX-1 inhibition activity was quantified with
a COX fluorescent inhibitor screening assay kit (Cayman Chemicals) accord-
ing to the manufacturer’s directions. More details regarding the synthesis of
PGA-TriEG-Diclof and its characterization in solution and in multilayer films
are provided in SI Materials and Methods.
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